The price of Pacific Biosciences of California Inc. (NASDAQ: PACB) closed at $12.56 in the last session, down -3.83% from day before closing price of $13.06. In other words, the price has decreased by -$0.50 from its previous closing price. On the day, 4410420 shares were traded. PACB stock price reached its highest trading level at $13.12 during the session, while it also had its lowest trading level at $12.22.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Ratios:
We take a closer look at PACB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.50 and its Current Ratio is at 3.70. In the meantime, Its Debt-to-Equity ratio is 1.30 whereas as Long-Term Debt/Eq ratio is at 1.30.
Upgrades & Downgrades
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 18 when Farmer Michele sold 5,165 shares for $12.59 per share. The transaction valued at 65,027 led to the insider holds 107,577 shares of the business.
Ericson William W. sold 7,541 shares of PACB for $67,115 on Mar 15. The Director now owns 18,795 shares after completing the transaction at $8.90 per share. On Mar 03, another insider, HENRY CHRISTIAN O, who serves as the insider of the company, sold 13,769 shares for $9.49 each. As a result, the insider received 130,709 and left with 1,222,939 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PACB now has a Market Capitalization of 2.82B and an Enterprise Value of 3.00B. For the stock, the TTM Price-to-Sale (P/S) ratio is 23.42 while its Price-to-Book (P/B) ratio in mrq is 4.39. Its current Enterprise Value per Revenue stands at 22.38 whereas that against EBITDA is -9.80.
Stock Price History:
Over the past 52 weeks, PACB has reached a high of $14.20, while it has fallen to a 52-week low of $3.85. The 50-Day Moving Average of the stock is 10.88, while the 200-Day Moving Average is calculated to be 9.10.
Shares Statistics:
According to the various share statistics, PACB traded on average about 3.64M shares per day over the past 3-months and 3.23M shares per day over the past 10 days. A total of 242.03M shares are outstanding, with a floating share count of 206.29M. Insiders hold about 0.80% of the company’s shares, while institutions hold 88.90% stake in the company. Shares short for PACB as of Apr 27, 2023 were 25.44M with a Short Ratio of 25.44M, compared to 25.1M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 10.18% and a Short% of Float of 11.38%.
Earnings Estimates
The company has 10 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.32 for the current quarter, with a high estimate of -$0.28 and a low estimate of -$0.36, while EPS last year was -$0.32. The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.25 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.2 and -$1.35 for the fiscal current year, implying an average EPS of -$1.26. EPS for the following year is -$1.04, with 9 analysts recommending between -$0.84 and -$1.18.
Revenue Estimates
According to 8 analysts, the current quarter’s revenue is expected to be $40.5M. It ranges from a high estimate of $42.8M to a low estimate of $38.04M. As of the current estimate, Pacific Biosciences of California Inc.’s year-ago sales were $35.47M, an estimated increase of 14.20% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $46.64M, an increase of 31.80% over than the figure of $14.20% in the same quarter last year. There is a high estimate of $48.83M for the next quarter, whereas the lowest estimate is $45.6M.
A total of 9 analysts have provided revenue estimates for PACB’s current fiscal year. The highest revenue estimate was $185.19M, while the lowest revenue estimate was $174M, resulting in an average revenue estimate of $179.02M. In the same quarter a year ago, actual revenue was $128.3M, up 39.50% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $265.17M in the next fiscal year. The high estimate is $289.68M and the low estimate is $235.5M. The average revenue growth estimate for next year is up 48.10% from the average revenue estimate for this year.
